UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 9, 2023  (March 8, 2023)

Future Health ESG Corp.

(Exact name of registrant as specified in its charter)

Registrant’s telephone number, including area code: (833) 388-8734

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

On March 8, 2023, the board of directors of Future Health ESG Corp. (the “Company”) declared a special warrant dividend providing that all holders of record of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) as of the record date of March 21, 2023 are to receive one warrant for each share of Common Stock held. The warrant dividend is being issued in connection with the “Non-redemption Incentive Program” as described in the definitive proxy statement on Schedule 14A the Company filed with the Securities and Exchange Commission (the “SEC”) on November 22, 2022. The warrant dividend is expected to be issued on or about March 28, 2023. Each warrant will entitle the holder to purchase one share of Common Stock at an exercise price of $10.00 per share following the closing of the Company’s initial business combination and prior to December 31, 2028 and will include an antidilution feature wherein the exercise price will be adjusted on the second anniversary of closing the Company’s initial business combination (the “Adjustment Date”) to the lower of $10.00 or the volume weighted average price of the Common Stock during the five trading days immediately preceding the Adjustment Date.

The warrants are not expected to be listed on The Nasdaq Capital Market. The shares of Common Stock issuable upon the exercise of the warrants are expected to be registered on a registration statement on Form S-4 (the “Registration Statement”) the Company intends to file with the SEC in connection with its initial business combination.

This Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. Any offer of securities covered by the Registration Statement will be made solely by means of a prospectus included in the Registration Statement.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.